Belenos Biosciences
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | TSLP + IL-13Multispecific antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous Urticaria |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
July 2027 (1)
November 2027 (1)
2028 (3)
March 2028 (1)
May 2028 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.